This is higher than the typical weight loss recommendation because the goal is supporting muscle protein synthesis rather than simply preserving existing muscle
This is a signal-discovery instrument: proportions are among side-effect-disclosing posters rather than population rates, and symptom posts are structurally under-represented against progress posts, so it supports vocabulary and theme prominence, not magnitude
It is a legitimate question for that drug class, but it is a completely different question from ours
Both are made by the Danish company Novo Nordisk
But if study endpoints measure lasting structural brain changes, synaptic density, neuroprotection, or recovery from injury, the biological evidence supports intermittent administration
This approach is supported by observational data showing 6070% weight-loss retention over 2+ years at lower doses